LIG
CPRX

Lokken Investment Group’s Catalyst Pharmaceutical CPRX Stock Holding History

Lokken Investment Group’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$316K Sell
16,050
-2,048
-11% -$42.1K 0.11% 113
2025
Q2 		$393K Buy
18,098
+3,799
+27% +$89.7K 0.15% 94
2025
Q1 		$347K Buy
+14,299
New +$322K 0.15% 95

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Fundsmith LLP
Fundsmith LLP London, United Kingdom $12.8B AUM 6.9% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Lokken Investment Group's CPRX Position: Q3 2025 in Review

Lokken Investment Group reduced its Catalyst Pharmaceutical (CPRX) stake by 11% in Q3 2025, selling an estimated $42.1K and leaving 16,050 shares worth $316K. The position accounts for 0.11% of the portfolio, ranked #113.

Lokken Investment Group first reported a position in CPRX in Q1 2025 and has held it in 3 quarters since. The position peaked at $393K in Q2 2025. 360 funds tracked by Wall St. Rank hold CPRX as of Q3 2025.

  • Lokken Investment Group held 16,050 shares of Catalyst Pharmaceutical worth $316K as of Q3 2025.
  • Lokken Investment Group sold 2,048 Catalyst Pharmaceutical shares in Q3 2025, an estimated $42.1K.
  • Catalyst Pharmaceutical made up 0.11% of Lokken Investment Group's portfolio in Q3 2025, its #113 holding.
  • Lokken Investment Group first reported a position in Catalyst Pharmaceutical in Q1 2025 and has held it in 3 quarters since.
  • Lokken Investment Group's Catalyst Pharmaceutical position peaked at $393K in Q2 2025.
  • 360 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q3 2025.

Based on Lokken Investment Group's 13F filing for Q3 2025, filed 5 Nov 2025.